Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Bristol-Myers Squibb Shares Intellectual Property Rights of Reyataz With Medicines Patent Pool

December 12, 2013

"Bristol-Myers Squibb is to share intellectual property rights on an important HIV/AIDS drug in a patent pool designed to make treatments more widely available in poor countries," Reuters reports. The licensing deal between the Medicines Patent Pool (MPP) and Bristol "will enable generic drug firms around the world to produce affordable versions of atazanavir, [sold] under the brand name Reyataz, and to combine it with other medicines to make treatment easier," the news agency notes (Hirschler, 12/12). "This is the MPP's first agreement covering a [WHO]-preferred second-line therapy. The WHO estimates there will be over one million people on second-line treatment by 2016, and many more will need access to these therapies," according to an MPP

View Full Article


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Drug Patent Policies

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement